reason report
bottom line report financi result provid
pipelin updat larg consist expect
head neck hrasm scchn studi aim-hn track
initi continu view well posit
manag team execut tipifarnib develop
strategi continu view tipifarnib activ drug
manag safeti profil recal licens world-wide right
tipifarnib indic virolog janssen op
previous evalu tipifarnib broadli across variou hematolog
solid tumor limit success believ precis
medicin approach develop tipifarnib biomarker-defin patient
offer opportun improv past effort clinic updat
includ addit tipifarnib data hematolog malign
like view repres overlook
import driver upsid vs street expect addit initi
phase erk inhibitor data solid tumor expect
although expect data preliminari given studi
still dose-escal reiter op pt
registration-direct tipifarnib scchn studi aim-hn track
initi recal previous disclos encourag
feedback end phase ii fda meet detail
plan aim-hn studi link estim aim-hn studi
would take year enrol addit plan
initi hra screen outcom studi seq-hn vs
previous synchron aim-hn seq-hn protocol
oper cost effici
clinic updat includ addit data run-
hn studi on-going phase ii studi tipifarnib hrasm scchn
biomarker-enrich data on-going phase ii studi
tipifarnib hematolog malign like
view repres overlook import driver upsid
vs street expect earn call disclos
on-going phase ii studi chronic myelomonocyt leukemia cmml
amend also includ acut myeloid leukemia aml
data solid tumor continu expect although expect
data preliminari given studi still dose-escal
guid suffici cash fund oper
end cash equival
multipl dr tgr
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
rate share outperform view lead pipelin program
tipifarnib farnesyltransferas inhibitor activ drug manag safeti profil
licens world-wide right tipifarnib indic virolog janssen
previous evalu tipifarnib broadli across variou hematolog solid tumor
limit success believ precis medicin approach develop tipifarnib
biomarker-defin patient offer opportun improv past effort base review
literatur medacorp kol check believ investor focu continu
lead clinic asset tipifarnib inhibitor menin-ml mix lineag
price target base blend dcf analysi revenu
multipl analysi assign valu probability-weight us sale tipifarnib hra mutant
squamou cell carcinoma head neck scchn probabl success hra
mutant squamou non-smal cell lung cancer nsclc probabl success hra
mutant solid tumor probabl success peripher cell lymphoma
probabl success myelodysplast syndrom md probabl success
cmml probabl success assum royalti ex-u tipifarnib sale
futur partnership earlier stage program menin-ml inhibitor repres
upsid valuat use discount rate termin growth rate
pipelin program face clinic regulatori develop risk well commerci
intellectu properti risk also face execut risk financi risk may
addit financ need turn cash flow posit
leerink partner estim compani file
chang
oper
invest
financ
leerink partner estim compani file
pipelin upcom event
janssen
potenti acut
hrasm solid tumor
